James L Lordan
Overview
Explore the profile of James L Lordan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
801
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fisher A, White M, Goudie N, Kershaw A, Phillipson J, Bardgett M, et al.
BMJ Open Respir Res
. 2024 May;
11(1).
PMID: 38724453
Background: Long-term survival after lung transplantation is limited compared with other organ transplants. The main cause is development of progressive immune-mediated damage to the lung allograft. This damage, which can...
2.
Stubbs H, Cannon J, Knightbridge E, Durrington C, Roddis C, Gin-Sing W, et al.
BMJ Open Respir Res
. 2024 Mar;
11(1).
PMID: 38519115
Background: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a biomarker of cardiac ventricular wall stress that is incorporated into pulmonary hypertension (PH) risk stratification models. Sendaway sampling may enable patients to...
3.
Leong S, Bos S, Lordan J, Nair A, Fisher A, Meachery G
BMJ Open Respir Res
. 2023 Feb;
10(1).
PMID: 36854571
Background: Interstitial lung disease (ILD) has emerged as the most common indication for lung transplantation globally. However, post-transplant survival varies depending on the underlying disease phenotype and comorbidities. This study...
4.
Jones R, De Bie E, Groves E, Zalewska K, Swietlik E, Treacy C, et al.
Am J Respir Crit Care Med
. 2022 Mar;
206(1):81-93.
PMID: 35316153
Autoimmunity is believed to play a role in idiopathic pulmonary arterial hypertension (IPAH). It is not clear whether this is causative or a bystander of disease and if it carries...
5.
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma
Busby J, Matthews J, Chaudhuri R, Pavord I, Hardman T, Arron J, et al.
Eur Respir J
. 2021 Sep;
59(4).
PMID: 34561291
Background: Understanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease management. Methods: We reviewed patient choice to...
6.
Heaney L, Busby J, Hanratty C, Djukanovic R, Woodcock A, Walker S, et al.
Lancet Respir Med
. 2020 Sep;
9(1):57-68.
PMID: 32916135
Background: Asthma treatment guidelines recommend increasing corticosteroid dose to control symptoms and reduce exacerbations. This approach is potentially flawed because symptomatic asthma can occur without corticosteroid responsive type-2 (T2)-driven eosinophilic...
7.
Peacock A, Ling Y, Johnson M, Kiely D, Condliffe R, Elliot C, et al.
Pulm Circ
. 2020 Apr;
10(1):2045894020914851.
PMID: 32284847
Patients classified as idiopathic pulmonary arterial hypertension (defined as Group 1 on European Respiratory Society (ERS)/European Cardiac Society (ESC) criteria) may have evidence of minor co-existing lung disease on thoracic...
8.
Price L, Dimopoulos K, Marino P, Alonso-Gonzalez R, McCabe C, Kemnpy A, et al.
Thorax
. 2017 Sep;
72(11):1035-1045.
PMID: 28904006
Treatment of acute emergencies in patients with pulmonary arterial hypertension (PAH) can be challenging. In the UK and Ireland, management of adult patients with PAH is centred in eight nationally...
9.
Sithamparanathan S, Nair A, Thirugnanasothy L, Coghlan J, Condliffe R, Dimopoulos K, et al.
J Heart Lung Transplant
. 2017 Feb;
36(7):770-779.
PMID: 28190786
Background: Portopulmonary hypertension (PoPH) is a rare condition associated with poor survival, and the effect of modern therapies that target pulmonary arterial hypertension (PAH) on long-term outcome is unknown. This...
10.
Sithamparanathan S, Thirugnanasothy L, Clark S, Dark J, Fisher A, Gould K, et al.
Respir Med
. 2016 Aug;
117:103-8.
PMID: 27492519
Background: Lung transplant recipients have reduced long-term survival compared with other solid organ recipients. There is a lack of published data on the characteristics of very long term survivors. Methods:...